Researchers have found a metabolite in Burmese pythons that suppresses appetite in mice without some of GLP-1's side effects. And humans make it, too.
New research reaffirms that GLP-1s can help prevent heart attacks, but only as long as you're taking them.
Eli Lilly has issued a new warning against buying compounded versions of its drug tirzepatide, claiming to have found potentially dangerous impurities.
The companies' new partnership could signal the beginning of the end for compounded GLP-1s.
Over a 24 week period, people on UBT251 lost up to 20% of their body weight on average.
A new review finds no convincing evidence that drugs like Ozempic raise people's risk of common thyroid cancers.
The lawsuit is the latest in an escalating feud between the Danish pharmaceutical and telehealth company.
In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo.
Poison control calls involving GLP-1 medications like semaglutide and tirzepatide have dramatically risen in recent years.
Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose some weight.
People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.
People taking an obesity drug typically regain weight, a new review finds, often even quicker than people who lose weight through lifestyle changes alone.
It's the first GLP-1 pill approved for treating obesity.
Despite everything, science goes on.
New research finds that people taking GLP-1 tend to spend less money grocery shopping, especially on snacks.
People who switched from semaglutide or tirzepatide to orforglipron largely maintained their weight loss.
Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.
A new study finds a possible association between GLP-1 drugs like semaglutide and chronic cough, though the authors are calling for more research.
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.
New research suggests that people taking GLP-1 therapy are less likely to die from colorectal cancer.
